QPS Announces the Acquisition of Xendo Drug Development

This European Acquisition Expands QPS' Global Capabilities

NEWARK, Delaware and GRONINGEN, Netherlands, July 26, 2010 - QPS Holdings, LLC, a leading full-service GLP/GCP-compliant contract
research organization providing testing services to support preclinical and
clinical research and development, announced the completion of its
acquisition of Xendo Drug Development BV (XDD), headquartered in Groningen,
The Netherlands. XDD, a European contract research organization (CRO), will
be known as QPS Netherlands BV and become a wholly-owned subsidiary of QPS
Holdings, LLC.

(Logo: photos.prnewswire.com/prnh/20100726/PH39912LOGO )

(Logo: www.newscom.com/cgi-bin/prnh/20100726/PH39912LOGO )

With the completion of this acquisition, QPS further expands its global
range of linearly integrated resources and services:

    -- Drug discovery and development from preclinical to clinical studies
       for IND and NDA regulatory submissions.
    -- 300 clinical pharmacology beds on three continents - 24 in the
       Netherlands, 24 in Taiwan and 240 in the USA - one of the world's
       largest phase 1 site offerings.
    -- Start-up time for phase 1 clinical trials is four to six weeks,
       compared to several months in other European countries. Moreover,
       phase 2 can follow phase 1 without interruption. Many international
       pharmaceutical and biotech companies have conducted first entry into
       man (FIM) studies in the Netherlands. This is due to Netherlands'
       favorable regulatory environment, streamlined protocol approval
       process and lower cost of managing trials.
    -- One of the world's largest capacities in bioanalysis for small
       molecules and biologics, with global bioanalysis facilities in the
       USA, Europe and Asia.
    -- Complete ADME package for regulatory submissions from preclinical
       studies to radiolabeled human mass balance (including microdosing)
       studies.
    -- CNS drug research and development, such as Alzheimer therapy, from
       patient stratification, to the clinic, to in vivo imaging, to PK/PD
       correlation and efficacy evaluation, with clinical genotyping and
       specialized biomarker assay capability to support the pursuit of
       targeted therapies and personalized medicines.

XDD has state-of-the-art large and small molecule bioanalytical
laboratories and a dedicated 24-bed clinical pharmacology unit (CPU) located
at University Medical Center Groningen (UMCG). Established in 2004, this CPU
has performed over 100 clinical pharmacology studies - many of them first
entry into man (FIM) studies - across all major therapeutic areas. This
location provides comprehensive safety monitoring with 24/7 access to
hospital-based crash teams and clinical specialists. XDD also offers an
extensive database of healthy volunteers as well as special and patient
populations.

"Pooling our strengths will enable XDD and QPS to serve our clients even
better. Our leading capability in conducting high quality bioanalysis and
phase 1 studies, combined with our well established expertise in ADME,
genotyping and drug development process will make QPS an ideal drug
development partner for our pharmaceutical and biotech clients worldwide,"
said Ben Chien, Chairman, and CEO of QPS holdings.

"Joining the QPS organization enables XDD to realize its ambitions for
global growth. In terms of activities, size and location, QPS and XDD are a
perfect fit. Our combined operations in Asia, Europe and the US position us
ideally to expand our portfolios in the increasingly consolidated
pharmaceutical and biotechnology sector, our primary market," said Koos
Koops, XDD's former chief executive officer. Koops will head the XDD -QPS
Netherlands division of QPS.

"As both QPS and XDD facilities share the same high standards and
customer service philosophy, this merger will further strengthen our ability
to provide our clients with quality, services, and competitive pricing
worldwide," stated Ben Chien.

About Xendo

Established in 1999, XDD is a European CRO with extensive experience
conducting and staffing international Phase I to Phase IV clinical trials
across a broad range of therapeutic areas for a wide variety of clients. XDD
employs over 100 people, and provides early & late phase clinical
development, data management, biometrics, medical writing, bioanalysis and
resourcing solutions services. Further information is available at
www.xendo.com

About QPS

Founded in 1995, QPS (www.qps-usa.com) has bioanalysis and DMPK
facilities at its Newark, DE, USA headquarters, a laboratory in Taipei,
Taiwan, and phase 1 facility in Springfield, Missouri. QPS has been providing
quality services in regulated and non-regulated bioanalysis (LC/MS/MS,
immunoanalytical, and hybridization-ELISA), DMPK, protein biomarkers,
pharmacogenomics and pharmacogenetics markers, and phase 1 studies to its
clients worldwide.

Ben Chien, Ph.D., Chairman, President & CEO of QPS, +1-650-599-9445; or Koos Koops, MSc, CEO of Xendo Drug Development, +31-0-50-3048000